AI Terminal
SEED INNOVATIONS LIMITED
Regulatory Filings • Nov 29, 2021
7909_rns_2021-11-29_3d38d6f9-89fc-47b0-a9ec-cef9db4b56d6.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 9328T
Seed Innovations Limited
29 November 2021
Seed Innovations Limited / AIM: SEED / Sector: Closed End Investments
29 November 2021
SEED Innovations Limited ("SEED" or the "Company")
Change of Registered Address and Change of Administrator
SEED Innovations Limited, the AIM quoted company investing in fast growing and industry leading businesses with a focus on the medical cannabis, health, and wellness space, announces effective immediately a change in Administrator and Secretary to Obsidian Fund Services Limited. Following this change the registered office of the Company is now PO Box 343, Obsidian House, La Rue D'Aval, Vale, Guernsey GY6 8LB.
*** ENDS***
For further information on the Company please visit www.seedinnovations.co or contact:
| Ed McDermott / Lance de Jersey |
SEED Innovations Ltd | Email: [email protected] |
| James Biddle / Roland Cornish |
Beaumont Cornish Limited, Nomad |
Tel: +44 (0) 207 628 3396 |
| Isabella Pierre / Damon Heath |
Shard Capital Partners LLP | T: +44 (0)20 7186 9927 |
| Catherine Leftley / Isabel de Salis |
St Brides Partners Ltd, Financial PR |
Email: [email protected] |
Notes
SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
CROEAKFNAFPFFFA